The Role of Biomarkers and Companion / Complementary Diagnostics in Immuno-Oncology Trials
We recently held a well-attended webinar where Covance Chief Scientific Officer Steven M. Anderson, PhD, addressed immunotherapy development considerations and their implications for drug developers. We’ve recorded the webinar for you to view at your own convenience.
You’ll learn more about key considerations on a wide range of topics, including:
As the CSO of Covance, Dr. Anderson leads the development and implementation of scientific strategy throughout the various Covance business units, coordinating with the scientific teams in Early Development, Central Labs, Clinical Development, Market Access, and the LabCorp Diagnostics business.
